1,106 results on '"Taylor, Ian"'
Search Results
2. Motivational Processes in Physical Education
3. Volition in Sport and Exercise
4. A tale of two species: Disaggregating mixed historical catches of two most common skates in the Northeast Pacific Ocean
5. Self-control exertion and goal priming: Effects on time-to-exhaustion cycling performance.
6. Population genomics of coastal Pacific Hake
7. A Type-2 Fuzzy-Based Explainable AI System for Predictive Maintenance Within the Water Pumping Industry
8. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
9. Incorporating patient and public involvement (PPI) at the design stage of an early career physiotherapy researcher's funding application: A co-produced reflective case report
10. Limits of Market Society: European Perspectives 1
11. Official Remedies: Inquiries Under Section 432(2) of the Companies Act 1985
12. Motivation and Self-regulation in Sport and Exercise
13. Summary, Common Themes, and Future Directions
14. A Motivational Model of Endurance and Persistence
15. Introduction to Motivation and Self-Regulation in Sport and Exercise
16. Capitalism and Africa’s (infra)structural dependency
17. Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativa
18. Fast Bayesian Record Linkage for Streaming Data Contexts
19. SSMSE: An R package for Management Strategy Evaluation with Stock Synthesis Operating Models
20. Mechanism of substrate hydrolysis by the human nucleotide pool sanitiser DNPH1
21. Introduction
22. Rethink Design Guide
23. Universities and Colleges
24. Introduction: Small States and the Migrant Crisis in Context
25. The Political Economy of Crime
26. Responsible government and responsible business: the challenge of harnessing CSR in a new epoch
27. Toward Enabling Reproducibility for Data-Intensive Research Using the Whole Tale Platform
28. The Political Economy of Africa
29. Afro-Asian Trade and the “Africa Rising” Story
30. Direct m6A recognition by IMP1 underlays an alternative model of target selection for non-canonical methyl-readers
31. Affinity-enhanced RNA-binding domains as tools to understand RNA recognition
32. Attenuation of reverse transcriptase facilitates SAMHD1 restriction of HIV-1 in cycling cells
33. In silico and multi-dimensional functional interrogation of tissue Tregs reveals novel therapeutics for autoimmunity and inflammation
34. Stage‐specific drivers of Pacific hake (Merluccius productus) recruitment in the California Current Ecosystem
35. Professionalism and the Coverage of Protest: How an Ethos of Professionalism in Journalism Guided the Ways in Which Journalists Reported on an Anti-Trump Demonstration
36. Abstract 432: Mechanisms of acquired resistance to ARV-471, a novel PROTAC® estrogen receptor degrader
37. Abstract 3075: Enhanced efficacy of ARV-471, a novel PROTAC® estrogen receptor degrader, in combination with targeted agents in estrogen receptor-positive (ER+) breast cancer models
38. Supplementary Figure 5 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
39. Supplementary Table 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
40. Supplementary Figure Legend from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
41. Supplementary Figure 4 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
42. Supplementary Figure 7 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
43. Data from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
44. Supplementary Figure 3 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
45. Supplementary Figure 7 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
46. Supplementary Figure 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
47. Supplementary Table 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
48. Data from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
49. Supplementary Table 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
50. Supplementary Table 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.